Avid Bioservices Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices or view top-rated stocks.

Wall Street analysts have given Avid Bioservices a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avid Bioservices wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Avid Bioservices saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,850,000 shares, an increase of 24.4% from the June 15th total of 3,900,000 shares. Based on an average trading volume of 564,800 shares, the short-interest ratio is presently 8.6 days. Currently, 8.0% of the company's shares are short sold.
View Avid Bioservices' Short Interest.

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Tuesday, September 7th 2021.
View our earnings forecast for Avid Bioservices.

Avid Bioservices, Inc. (NASDAQ:CDMO) announced its earnings results on Monday, June, 28th. The biopharmaceutical company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.05. The biopharmaceutical company had revenue of $27.61 million for the quarter, compared to the consensus estimate of $20.70 million. Avid Bioservices had a net margin of 11.69% and a trailing twelve-month return on equity of 17.31%.
View Avid Bioservices' earnings history.

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDMO stock has increased by 472.5% and is now trading at $25.82.
View which stocks have been most impacted by COVID-19.

Avid Bioservices shares reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

Avid Bioservices issued an update on its FY 2022 earnings guidance on Tuesday, July, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $115 million-$117 million, compared to the consensus revenue estimate of $112.15 million.

3 equities research analysts have issued 1-year price objectives for Avid Bioservices' shares. Their forecasts range from $27.00 to $29.00. On average, they anticipate Avid Bioservices' stock price to reach $28.00 in the next year. This suggests a possible upside of 8.4% from the stock's current price.
View analysts' price targets for Avid Bioservices or view top-rated stocks among Wall Street analysts.

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Avid Bioservices include I-Mab (IMAB), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Apellis Pharmaceuticals (APLS), Blueprint Medicines (BPMC), Arvinas (ARVN), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Alkermes (ALKS), Hypera (HYPMY), Allakos (ALLK), Galapagos (GLPG), Lyell Immunopharma (LYEL) and Arena Pharmaceuticals (ARNA).
View all of CDMO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Avid Bioservices' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AltraVue Capital LLC (1.85%), Kornitzer Capital Management Inc. KS (1.17%), New York State Common Retirement Fund (0.72%), Peregrine Capital Management LLC (0.54%), Calamos Advisors LLC (0.39%) and Fisher Asset Management LLC (0.19%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Mark R Ziebell, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices.

CDMO stock was sold by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund, and Fisher Asset Management LLC. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, and Mark R Ziebell.
View insider buying and selling activity for Avid Bioservices or view top insider-selling stocks.

CDMO stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Monarch Partners Asset Management LLC, Calamos Advisors LLC, Jackson Creek Investment Advisors LLC, Victory Capital Management Inc., Arizona State Retirement System, Carderock Capital Management Inc., and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices or or view top insider-buying stocks.

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDMO stock can currently be purchased for approximately $25.82.

Avid Bioservices has a market capitalization of $1.58 billion and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.06 on an earnings per share basis.

Avid Bioservices employs 222 workers across the globe.

The official website for Avid Bioservices is www.avidbio.com.

Avid Bioservices is headquartered at 2642 Michelle Drive Suite 200, TUSTIN CA, 92780.

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]